Closure of patent foramen ovale: when and how?

Curr Vasc Pharmacol. 2007 Oct;5(4):322-7. doi: 10.2174/157016107782023370.

Abstract

Percutaneous closure of a patent foramen ovale (PFO) was performed in 98 consecutive patients (mean age 52.5 +/- 13 years, 61 women). Indications included recurrent transient ischaemic attack (47%), cryptogenic stroke (34%), peripheral embolism (11%), disabling migraine with aura (4%), professional scuba diving (1 pt) and severe platypnea-orthodeoxia syndrome (1 pt). Each PFO was characterized by transesophageal echocardiography (TEE) according to anatomy, degree of shunt (1-mild, 2-moderate, 3-severe), right atrial anatomical features relevant for PFO closure (such as presence of an Eustachian valve, Chiari network, lipomatosis or absence of septum secundum) with a new classification scheme. According to this classification successful device delivery was obtained in 100% of pts. Major complications included heparin-induced thrombocytopenia in 1 pt and device dislodgment in 1 pt; minor complications were mostly related to the catheter introduction site (2 pts) and mild immediate shunt (2 pts). In conclusion, percutaneous PFO closure based on strict anatomic criteria is a safe procedure with minimal periprocedural complications.

MeSH terms

  • Cardiac Catheterization* / adverse effects
  • Decompression Sickness / complications
  • Diving
  • Dyspnea / etiology
  • Echocardiography, Transesophageal
  • Embolism / etiology
  • Embolism / prevention & control
  • Equipment Failure
  • Female
  • Foramen Ovale, Patent / complications*
  • Foramen Ovale, Patent / diagnostic imaging
  • Foramen Ovale, Patent / therapy*
  • Humans
  • Hypoxia / etiology
  • Ischemic Attack, Transient / etiology
  • Ischemic Attack, Transient / prevention & control
  • Male
  • Middle Aged
  • Migraine with Aura / etiology
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prostheses and Implants
  • Recurrence
  • Stroke / etiology
  • Stroke / prevention & control
  • Syndrome
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors